Evaluation of anticancer activity of α-defensins purified from neutrophils trapped in leukoreduction filters.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 May 2019
Historique:
received: 21 02 2019
revised: 25 03 2019
accepted: 28 03 2019
pubmed: 3 4 2019
medline: 21 5 2019
entrez: 3 4 2019
Statut: ppublish

Résumé

The α-defensins or human neutrophil peptides (HNP 1-3) that exist in azurophilic granules are found to have anticancer activity. The pattern of disulfide bonds in α-defensins is crucial for the functional properties. Therefore, synthesis using the chemical and recombinant approaches is a challenging. A safe source for the production of α-defensins can be the use of leukoreduction filters in blood banks that contain large quantities of neutrophils and are discarded after use. The aim of this study was to purify α-defensins from neutrophils trapped in leukofilters and to investigate its anticancer activity. Immunoprecipitation was performed to purify α-defensins and the presence of protein was confirmed by Western Blot. The Jurkat T-cell line was incubated with different concentrations (5, 10 and 15 μg/ml) of purified HNP1-3 for 16 h. Cell viability was measured using a WST-1 assay and apoptosis was analyzed for Annexin V/PI markers. Caspase-3/7 activity was determined using fluorescence assay. The effects of purified α-defensins were compared to commercial HNP 1-3. Purified HNP 1-3 decreased the viability at 10 and 15 μg/ml and commercial HNP 1-3 at 15 μg/ml concentrations. Following to the purified HNP1-3 treatment, the percentage of Annexin V positive population and caspase-3 activity were significantly increased compared to control (p = 0.000 and p = 0.001, respectively) and commercial HNP1-3 (p = 0.034 and p = 0.018, respectively). Results indicated the anticancer activity of HNP1-3 which can be used as future chemotherapeutic drugs. Furthermore, leukofilters can be considered as economic source for purifying these peptides.

Identifiants

pubmed: 30935951
pii: S0024-3205(19)30243-7
doi: 10.1016/j.lfs.2019.03.072
pii:
doi:

Substances chimiques

Anti-Infective Agents 0
Antineoplastic Agents 0
alpha-Defensins 0
human neutrophil peptide 1 0
human neutrophil peptide 2 0
human neutrophil peptide 3 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

249-254

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Shirin Ferdowsi (S)

Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

Ali Akbar Pourfathollah (AA)

Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran; Tarbiat Modares University, Faculty of Medical Sciences, Department of Immunology, Tehran, Iran. Electronic address: Pourfa@ibto.ir.

Fatemeh Amiri (F)

Department of Medical Laboratory Sciences, School of Para Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Mohammad Hessam Rafiee (MH)

Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

Afsaneh Aghaei (A)

Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH